EvolVeritas Ltd. is a spinoff biotech company founded by scientists studying the molecular mechanism of complement activation through structure-driven protein engineering, directed protein evolution and enzymology.  Our mission is to pick up and further develop therapeutically promising results of academic discoveries, which open new avenues for treating severe diseases with high unmet medical needs. EvolVeritas is properly equipped and well-positioned to become a significant player in generating research tool ligands for discovering new drug targets and developing drug candidate compounds by developing specific protein molecules. We bring breakthroughs in therapeutic areas such as ischemic reperfusion injury, thrombosis, and COVID-19. The company values innovation, scientific excellence, integrity, and partnership. Our goals are to maximally explore the therapeutic opportunities of our existing patents by addressing as many therapeutic areas as possible. Developing additional novel human protein-based drug candidates in therapeutic areas with high unmet medical needs.